## **Committee on Energy and Commerce**

U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1.	Your Name: Ann Maxwell
2.	Your Title: Assistant Inspector General for Evaluation
3.	The Entity(ies) You are Representing:
4.	Are you testifying on behalf of the Federal, or a State or local government entity?  Yes  No
5.	Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.
r	
	Di // l disclosses forms
0.	Please attach your curriculum vitae to your completed disclosure form.
Si	gnature:Date:

Ann Maxwell
Assistant Inspector General for Evaluations and Inspections
Office of Evaluation and Inspections
Office of Inspector General
Department of Health and Human Services

Ann Maxwell is Assistant Inspector General for Evaluations with the Office of Evaluation and Inspections (OEI), Office of Inspector General (OIG), Department of Health and Human Services (HHS). She has been with OIG, in various roles, for 17 years.

As Assistant Inspector General for Evaluations, Ms. Maxwell helps manage OEI's daily operations. OEI conducts national evaluations of HHS programs from a broad, issue-based perspective. These evaluations offer practical recommendations to improve the efficiency and effectiveness of HHS programs, with a focus on preventing fraud, waste, and abuse. In this role, Ms. Maxwell is also responsible for strategic planning across multiple subject-matter portfolios, including public health, Medicaid, food and drug safety, emergency preparedness, and prescription drugs. Ms. Maxwell also oversees the State Medicaid Fraud Control Units, which investigate and prosecute providers for Medicaid fraud as well as for patient abuse and neglect.

Prior to this position, Ms. Maxwell was the Regional Inspector General for OEI's Chicago regional office. In this role, she directed national studies in Medicare, Medicaid, public health, and child welfare. Ms. Maxwell has focused significant efforts on evaluating prescription drug benefits under Medicare, Medicaid, and the 340B Drug Pricing Program. Her office's evaluations of Medicaid drug pricing contributed to significant changes in the way Medicaid reimburses for prescription drugs, implemented in the Deficit Reduction Act of 2005. Her office's evaluations of the 340B Drug Pricing Program led to strengthened oversight of the program, mandated in the Patient Protection and Affordable Care Act of 2010.

Ms. Maxwell's work has received numerous awards, including Bronze Medal for Exemplary Leadership, the Excellence in Program Evaluation Award, and the Award for Excellence in Evaluation granted by the President's Council on Integrity and Efficiency.

Ms. Maxwell received a B.A. in Sociology and Economics from Kalamazoo College. She also holds a master's degree from the University of Chicago's School of Social Service Administration, where her studies focused on public policy and program evaluation.